Nanoparticle mediated targeting of VEGFR and cancer stem cells for cancer therapy

Vascular Cell

Volumn 3, Issue , 2011, Pages

  Ambasta, Rashmi K ^a   Sharma, Archita ^a   Kumar, Pravir ^a,b  

^a VIT UNIVERSITY   (India)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer stem cell; Cancer therapy; Nanoparticle; VEGF

Indexed keywords

3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE DIMETHYLGLYCINE ESTER; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ALACIZUMAB PEGOL; AXITINIB; BAY 93 4006; BEVACIZUMAB; CEDIRANIB; CELL MARKER; GOLD NANOPARTICLE; GW786024; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRON OXIDE; MOTESANIB; NANOPARTICLE; RAMUCIRUMAB; SOMATOMEDIN; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN A; VASCULOTROPIN ANTIBODY; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VATALANIB;

ANGIOGENESIS; ANTIANGIOGENIC GENE THERAPY; CANCER RECURRENCE; CANCER STEM CELL; CARDIOVASCULAR RISK; CELL PROLIFERATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; ENDOTHELIUM CELL; GENE TARGETING; HUMAN; HYPERTENSION; HYPOXIA; METASTASIS INHIBITION; NANOTECHNOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW; SIDE EFFECT;

EID: 84863420749     PISSN: None     EISSN: 2045824X     Source Type: Journal    
DOI: 10.1186/2045-824X-3-26     Document Type: Review

References (68)

1. Use of angiogenesis inhibitors in tumour treatment. Fayette Jerome, Soria Jean-Charles, Armand Jean-Pierre, European Journal of Cancer 2005 41 1109 1116 10.1016/j.ejca.2005.02.017 15911233 (Pubitemid 40725568)
2. Anti-angiogenesis and angioprevention: mechanisms, problems and perspectives Cancer Detection and Prevention. Bisacchi D, Benelli R, Vanzetto C, Ferrari N, Tosetti F, Albini A, 2003 27 229 238
3. Lymphatic endothelium: a new frontier in metastasis research. Karkkainen MJ, Makinen T, Alitalo K, Nat Cell Biol 2002 4 2 5 10.1038/ncb0102-e2 11780131 (Pubitemid 34071967)
4. Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor Current Status and Future Challenges in Cancer Therapy. Hsu Jerry Y, Wakelee Heather A, Biodrugs 2009 23 5 289 304 1173-8804/09/0005-0289/ 10.2165/11317600-000000000-00000 19754219
5. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. Dikov MM, Ohm JE, Ray N, Tchekneva EE, Burlison J, Moghanaki D, Nadaf S, Carbone DP, J Immunology 2005 174 215 222 (Pubitemid 40007407)
6. The related FLT4, FLT1, and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells. Kaipainen A, Korhonen J, Pajusola K, Aprelikova O, Terman BI, Alitalo K, J Exp Med 1993 178 2077 2088 10.1084/jem.178.6.2077 8245783 (Pubitemid 23344864)
7. A novel function for dendritic cell: Clearance of VEGF via VEGF receptor-1. Yi Xie, Jianqing Fan, Juhua Chen, Fang-Ping Huang d, Brian Cao, Tam Paul KH, Yi Ren, Biochemical and Biophysical Research Communications 2009 380 243 248T 10.1016/j.bbrc.2009.01.043 19167346
8. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Shibuyaa Masabumi, Claesson-Welsh Lena, Experimental Cell Research 2006 312 549 560 10.1016/j.yexcr.2005.11.012 16336962 (Pubitemid 43290332)
9. VEGF receptor signal transduction. Claesson-Welsh Matsumoto L, Sci STKE 2001 E21
10. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Saharinen P, Tammela T, Karkkainen MJ, Alitalo K, Trends Immunology 2004 25 387 395 10.1016/j.it.2004.05.003 (Pubitemid 38780956)
11. NC-and VEGF-A-induced angiogenesis in vitro. Tille Jean-Christophe, Wang Xueyan, Lipson Kenneth E, Gerald McMahon, Napoleone Ferrara, Zhenping Zhu, Hicklin Daniel J, Sleeman Jonathan P, Ulf Eriksson, Kari Alitalo, Peppera Michael S, Experimental Cell Research 2003 285 286 298 10.1016/S0014-4827(03)00053-3 12706123 (Pubitemid 36428960)
12. Vascular endothelial growth factors and receptors: Anti-angiogenic therapy in the treatment of cancer. Tugues Snia, Koch Sina, Gualandi Laura, Li Xiujuan, Claesson-Welsh Lena, Molecular Aspects of Medicine 2011 32 88 111 10.1016/j.mam.2011.04.004 21565214
13. VEGF enhancement of osteoclast survival and bone resorption involves VEGF receptor-2 signaling and 3-integrin. Yang Quanli, McHugh Kevin P, Patntirapong Somying, Xuesong Gu, Wunderlich Livius, Hauschka Peter V, Matrix Biology 2008 27 589 599 10.1016/j.matbio.2008.06.005 18640270
14. Tumor angiogenesis: the pivotal role of vascular endothelial growth factor. Marmé D, World Journal Of Urology 14 3 166 174
15. The Vascular Endothelial Growth Factor (VEGF) Signaling Pathway: A Therapeutic Target in Patients with Hematologic Malignancies The Oncologist. Giles Francis J, 2001 6 Suppl 5 32 39
16. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Roland CL, Dineen SP, Lynn KD, Sullivan LA, Dellinger MT, Sadegh L, Sullivan JP, Shames DS, Brekken RA, Mol Cancer Ther 2009 8 1761 1771 10.1158/1535-7163.MCT- 09-0280 19567820
17. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F, N Engl J Med 2004 350 2335 2342 10.1056/NEJMoa032691 15175435 (Pubitemid 38702844)
18. AVOREN Trial investigators Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, doubleblind phase III trial. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N, Lancet 2007 370 2103 2111 10.1016/S0140- 6736(07)61904-7 18156031 (Pubitemid 350296300)
19. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O'Bryant C, Chow LQ, Serkova NJ, Meropol NJ, Lewis NL, Chiorean EG, Fox F, Youssoufian H, Rowinsky EK, Eckhardt SG, J Clin Oncol 2010 28 780 787 10.1200/JCO.2009.23.7537 20048182
20. Development Of Angiogenesis Inhibitors To Vascular Endothelial Growth Factor Receptor 2. Current Status And Future Perspective. Keren Paz, Zhenping Zhu, Frontiers in Bioscience 2005 10 1415 1439 10.2741/1629 15769635
21. Challenges for patient selection with VEGF inhibitors. Longo R, Gasparini G, Cancer Chemother Pharmacol 2007 60 151 170 10.1007/s00280-006-0403-6 17370072 (Pubitemid 46742547)
22. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G, Cancer Res 2004 64 14 4931 41 10.1158/0008-5472.CAN-03- 3681 15256466 (Pubitemid 38924540)
23. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Herbst RS, Eberhardt WE, Germonpré P, Saijo N, Zhou C, Wang J, Li L, Kabbinavar F, Ichinose Y, Qin S, Zhang L, Biesma B, Heymach JV, Langmuir P, Kennedy SJ, Tada H, Johnson BE, Lancet Oncol 2010 11 619 626 10.1016/S1470-2045(10)70132-7 20570559
24. The angiogenic process as a therapeutic target in cancer. Bridges Esther M, Harris Adrian L, Biochemical Pharmacology 2011 81 1183 1191 10.1016/j.bcp.2011.02.016 21382350
25. Cellular and soluble markers of tumor angiogenesis: From patient selection to the identification of the most appropriate post resistance therapy. Bertolini Francesco, Marighetti Paola, Shaked Yuval, Biochimica et Biophysica Acta 2010 1806 131 137 20685298
26. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA, J Clin Oncol 2009 27 3584 3590 10.1200/JCO.2008.20.1293 19487381
27. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Beebe Jean S, Jani Jitesh P, Knauth Elisabeth, Goodwin Peter, Higdon Carla, Rossi Ann Marie, Emerson Erling, Finkelstein Martin, Floyd Eugenia, Harriman Shawn, Atherton Jim, Hillerman Steve, Soderstrom Cathy, Kou Kou, Gant Tom, Noe Mark C, Foster Barb, Rastinejad Farzan, Marx Matthew A, Schaeffer Tracey, Whalen Pamela M, Roberts W Gregory, Cancer Res 2003 63 7301 7309 14612527 (Pubitemid 37413471)
28. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarbá JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE, J Clin Oncol 2010 28 1061 8 10.1200/JCO.2009.23.9764 20100962
29. Sorafenib in advanced clear-cell renal-cell carcinoma. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, TARGET Study Group, N Engl J Med 2007 356 125 34 10.1056/NEJMoa060655 17215530 (Pubitemid 46089673)
30. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. Rosen LS, Kurzrock R, Mulay M, Van Vugt A, Purdom M, Ng C, Silverman J, Koutsoukos A, Sun YN, Bass MB, Xu RY, Polverino A, Wiezorek JS, Chang DD, Benjamin R, Herbst RS, J Clin Oncol 2007 25 2369 2376 10.1200/JCO.2006.07.8170 17557949 (Pubitemid 46999207)
31. Thrombosis associated with angiogenesis inhibitors. Elice Francesca, Rodeghiero Francesco, Falanga Anna, Rickles Frederick R, Best Practice & Research Clinical Haematology 2009 22 115 128 10.1016/j.beha.2009.01.001 22101635
32. Hypoxia inducible factors in cancer stem cells. Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmeland AB, Rich JN, British Journal of Cancer 2010 Cancer Research UK All rights reserved 0007-0920/10 2010 102 789 795 10.1038/sj.bjc.6605551 20104230
33. Improved delivery of angiogenesis inhibitors from PLGA:poloxamer blend micro- and nanoparticles. d'Angelo Ivana, Parajá Yolanda, Horvth Aniká Kéri Gyrgy, Rotonda Maria Immacolata La, Alonso María José Journal of Microencapsulation 2010 27 1 57 66 10.3109/ 02652040902954729 19545221
34. Stem cells, cancer, and cancer stem cells. Reya Tannishtha, Morrison Sean J, Clarke Michael F, Weissman Irving L, Nature 2001 414
35. Normal Stem Cells and Cancer Stem Cells: The Niche Matters. Li Linheng, Neaves William B, Cancer Res 2006 66 4553 4557 10.1158/0008-5472.CAN-05-3986 16651403
36. The elaboration of a critical framework for understanding cancer: the cancer stem cell hypothesis. Hemmings Chris, Pathology 2010 42 2 105 112 10.3109/00313020903488773 20085510
37. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM, Cancer Res 2006 66 9339 44 10.1158/0008-5472.CAN-06-3126 16990346 (Pubitemid 44623625)
38. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Liu Gentao, Yuan Xiangpeng, Zeng Zhaohui, Tunici Patrizia, Hiushan Ng, Abdulkadir1 Iman R, Lu Lizhi, Irvin Dwain, Black Keith L, Yu John S, Molecular Cancer 2006 5 67 10.1186/1476-4598-5-67 17140455 (Pubitemid 44942887)
39. Prowling wolves in sheep's clothing: the search for tumor stem cells. Alkatout Ibrahim, Kabelitz Dieter, Kalthoff Holger, Tiwari Sanjay, Biol Chem 2008 389 799 811 10.1515/BC.2008.094 18627316
40. Cancer Stem Cell Niche: The Place to Be. Borovski Tijana, Felipe De Sousa E Melo, Vermeulen Louis, Medema Jan Paul, Cancer Res 2011 71 3
41. Cancer Stem Cells: The Emerging Challenge of Drug Targeting. Besançon Roger, Valsesia-Wittmann Sandrine, Puisieux Alain, Claude Caron de Fromentel, Maguer-Satta Veronique, Current Medicinal Chemistry 2009 16 394 416 10.2174/092986709787315531 19199913
42. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors. Ferry AL, Eskens M, Verweij Jaap, A review, European journal of cancer 2006 42 3127 3139 10.1016/j.ejca.2006.09.015 (Pubitemid 44869016)
43. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Witte L, Hicklin DJ, Zhu Z, Pytowski B, Kotanides H, Rockwell P, Böhlen P, Cancer Metastasis Rev 1998 17 155 161 10.1023/A:1006094117427 9770111 (Pubitemid 28391949)
44. Prospective identification of tumorigenic breast cancer cells. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF, Proc Natl Acad Sci USA 2003 100 7 3983 8 10.1073/pnas.0530291100 12629218 (Pubitemid 36418143)
45. Generation of a functional mammary gland from a single stem cell. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, Wu L, Lindeman GJ, Visvader JE, Nature 2006 439 7072 84 8 10.1038/nature04372 16397499 (Pubitemid 43053633)
46. In vivo evidence for the role of CD44s in promoting breast cancer metastasis to the liver. Ouhtit A, Abd Elmageed ZY, Abdraboh ME, Lioe TF, Raj MH, Am J Pathol 2007 171 6 2033 9 10.2353/ajpath.2007.070535 17991717
47. Human breast cancer stem cell markers CD44 and CD24: enriching for cells with functional properties in mice or in man? Christine Fillmore, Charlotte Kuperwasse, Breast Cancer Research 2007 9 303 10.1186/bcr1673 17540049
48. Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas. Immervoll H, Hoem D, Sakariassen PO, Steffensen OJ, Molven A, BMC Cancer 2008 8 48 10.1186/1471-2407-8-48 18261235 (Pubitemid 351425942)
49. Identification of pancreatic cancer stem cells. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM, Cancer Res 2007 67 3 1030 7 10.1158/0008-5472.CAN-06-2030 17283135
50. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C, Cell Stem Cell 2007 1 3 313 23 10.1016/j.stem.2007.06.002 18371365 (Pubitemid 47355323)
51. Stem-like cells in bone sarcomas: implications for tumorigenesis. Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, Scott EW, Ghivizzani SC, Ignatova TN, Steindler DA, Neoplasia 2005 7 11 967 76 10.1593/neo.05394 16331882
52. Phenotypic characterization of human colorectal cancer stem cells. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C, Clarke MF, Proc Natl Acad Sci USA 2007 104 24 10158 63 10.1073/pnas.0703478104 17548814 (Pubitemid 47175279)
53. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. Choi Dongho, Won Lee Hyo, Yul Hur Kyung, Joon Kim Jae, Park Gyeong-Sin, Jang Si-Hyong, Soo Song Young, Jang Ki-Seok, Sam Paik Seung, World J Gastroenterol 2009 15 18 2258 2264 10.3748/wjg.15.2258 19437567
54. Cancer stem-like cells in human prostate carcinoma cells DU145: the seeds of the cell line? Wei C, Guomin W, Yujun L, Ruizhe Q, Cancer Biol Ther 2007 6 5 763 8 10.4161/cbt.6.5.3996 17592251 (Pubitemid 47328359)
55. Significance of CD90+ cancer stem cells in human liver cancer. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, Chu PW, Lam CT, Poon RT, Fan ST, Cancer Cell 2008 13 2 153 66 10.1016/j.ccr.2008.01.013 18242515 (Pubitemid 351163165)
56. Identification of a cancer stem cell in human brain tumors. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB, Cancer Res 2003 63 18 5821 8 14522905 (Pubitemid 37187480)
57. Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells. Kawasaki BT, Mistree T, Hurt EM, Kalathur M, Farrar WL, Biochem Biophys Res Commun 2007 364 4 778 82 10.1016/j.bbrc.2007.10.067 17964286 (Pubitemid 350103695)
58. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, Zheng BJ, Guan XY, Gastroenterology 2007 132 7 2542 56 10.1053/j.gastro.2007.04.025 17570225 (Pubitemid 46890873)
59. Stem cell marker expression in small cell lung carcinoma and developing lung tissue. Koch LK, Zhou H, Ellinger J, Biermann K, Holler T, von Rucker A, Buttner R, Gutgemann I, Hum Pathol 2008
60. Superparamagnetic nanoparticles as targeted probes for diagnostic and therapeutic applications. Xu C, Sun S, Dalton Trans 2009 29 5583 91 Epub 2009 May 1
61. Recent Progress in Syntheses and Applications of Dumbbell-like Nanoparticles. Wang C, Xu C, Zeng H, Sun S, Adv Mater 2009 21 30 3045 3052 10.1002/adma.200900320 20011128
62. Au-Fe3O4 dumbbell nanoparticles as dual-functional probes. Xu C, Xie J, Ho D, Wang C, Kohler N, Walsh EG, Morgan JR, Chin YE, Sun S, Angew Chem Int Ed Engl 2008 47 1 173 6 10.1002/anie.200704392 17992677
63. Cancer Nanotechnology: Opportunities And Challenges. Ferrari Mauro, Nature Publishing Group 2005 5
64. Cancer nanotechnology: application of nanotechnology in cancer therapy. Misra Ranjita, Acharya Sarbari, Sahoo Sanjeeb K, Drug Discovery Today 2010 15 19/20
65. Magnetic Nanoparticles for gene and drug delivery. McBain Stuart C, Yiu Humphery HR, Dobson Jon, Int Journal Of Nanomedicine 2008 3 2 169 180 (Pubitemid 352037850)
66. Preparation of Gold/Iron Oxide Composite Nanoparticles by a Laser-Soldering Method. Kawaguchi Kenji, Jaworski Jacek, Ishikawa Yoshie, Sasaki Takeshi, Koshizaki Naoto, IEEE Transactions On Magnetics 2006 42 10
67. Influence of Gold Nanoshell on Hyperthermia of Super Paramagnetic Iron Oxide Nanoparticles (SPIONs). Mohammad Faruq, Balaji Gopalan, Weber Andrew, Uppu Rao M, Kumar Challa SSR, J Phys Chem C Nanomater Interfaces 2010 1 20 3141 3146 21103390
68. Anti-Cancer Drug Loaded Iron-Gold Core-Shell Nanoparticles (Fe@Au) for Magnetic Drug Targeting. Kayal Sibnath, Ramanujan Raju Vijayaraghavan, Journal of Nanoscience and Nanotechnology 2010 10 1 13 10.1166/jnn.2010.1484